Phase 2Active, not recruiting

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma

Sponsor
US Oncology Research (Industry)
Enrollment
73 enrolled
Conditions
Multiple Myeloma; Myeloma Multiple; Kahler Disease; Myeloma, Plasma Cell; Myeloma-Multiple; Myelomatosis; Plasma Cell Myeloma
Interventions
Selinexor; Dexamethasone Oral; Daratumumab; Lenalidomide
Ages
adults, older adults
Registry
NCT04782687

Full record on ClinicalTrials.gov

From the registry

This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.

Primary outcomes

  • Complete Response Rate (CR)
  • Stringent Complete Response Rate (sCR)
  • Safety of Selinexor plus DRd

History

  1. Primary completion

  2. Last registry update

  3. Started

  4. Registered